Navigation Links
Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
Date:2/9/2009

europathic pain

Neuropathic pain is a major chronic pain condition. According to the most recent surveys, its estimated prevalence in the world's population is up to 6%, with many causes such as shingles, diabetes, antiviral or antitumor chemotherapy surgery, or low back disorders. Neuropathic pain does not respond well to usual painkillers. Worldwide market for neuropathic pain is estimated to reach 5 billion USD by 2010.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. It develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.65 billion in 2007.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

About Pharmaleads

Pharmaleads is a science driven drug discovery and early development company. Headquartered in Paris, France, Pharmaleads was founded in 2001 by Professors Bernard P. Roques, pharmacist and pharmacologist and PhD in physico-chemistry, Member of the French and European Academies of Sciences, and Marie-Claude Fournie-Zaluski, PhD in chemistry. Professors Roques and Fournie-Zaluski are the inventors of two marketed drugs, and have developed the concept of "physiological" treatment of pain which has led to PL37.

In 2004, Thierry Bourbie, alumnus from Polytechnique and Mines, PhD from '/>"/>

SOURCE Pharmaleads
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
2. Japanese Cancer Association and Debiopharm Honour Japanese Research
3. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
4. Debiopharm and EPFL Establish an Oncology Chair
5. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
6. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
7. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
8. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
10. Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University
11. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 UFP Technologies, a ... packaging has recently introduced a custom insulated shipping ... . The new insulated shipper solves the issue ... process. UFP Technologies’ BioShell is a universal storage ... storage, handling and shipping. The insulated shipper keeps ...
(Date:9/30/2014)... MA and Pittsburgh PA (PRWEB) September 30, 2014 ... Clinical Research Nurses ( IACRN), a non-profit ... Alliance for Clinical Research Excellence and Safety ... the signing of a strategic alliance agreement, setting ... IACRN’s vision is to enhance clinical research quality ...
(Date:9/29/2014)... military conflicts in Iraq and Afghanistan, more than 300,000 ... brain injury caused by exposure to bomb blasts ... IEDs. Symptoms of traumatic brain injury can range from ... more severe impairments in memory and cognition. , ... the critical importance and complexity of this problem, and ...
(Date:9/29/2014)... TORONTO , Sept. 29, 2014 /PRNewswire/ - Portage Biotech ... Exchange: PBT.U), is pleased to announce that its three ... of Portage, who advanced $ 100,000 each in July ... have their Notes and related Coupons converted into 3,500,001 ... and carried 5% coupon. Both the Note and the ...
Breaking Biology Technology:UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3
... Researchers performing ... have found that a combination of phenol based , ... array data than either method alone (1-3). ... of RiboPure RNA Isolation Kits are the first kits that combine , ...
... siRNA Expression Cassettes , ... enormous opportunities to study gene silencing. Unfortunately, ... vectors is labor and time intensive. , ... Cassette Kits provide a rapid PCR-based method for preparing , ...
... experiment depends on the efficient delivery of siRNA ... expression vehicles (plasmids, PCR fragments) into cells. Many , ... reagents to deliver these molecules into cultured mammalian , ... of reagent and the conditions under which it , ...
Cached Biology Technology:Improve RNA Isolation for Array Analysis and More 2Improve RNA Isolation for Array Analysis and More 3Improve RNA Isolation for Array Analysis and More 4Improve RNA Isolation for Array Analysis and More 5Improve RNA Isolation for Array Analysis and More 6GENE SILENCING WITH PCR PRODUCTS 2GENE SILENCING WITH PCR PRODUCTS 3GENE SILENCING WITH PCR PRODUCTS 4GENE SILENCING WITH PCR PRODUCTS 5GENE SILENCING WITH PCR PRODUCTS 6GENE SILENCING WITH PCR PRODUCTS 7GENE SILENCING WITH PCR PRODUCTS 8Choose the Right Transfection Agent for Your RNAi Experiment 2Choose the Right Transfection Agent for Your RNAi Experiment 3Choose the Right Transfection Agent for Your RNAi Experiment 4Choose the Right Transfection Agent for Your RNAi Experiment 5Choose the Right Transfection Agent for Your RNAi Experiment 6Choose the Right Transfection Agent for Your RNAi Experiment 7
(Date:9/30/2014)... and Howard Hughes Medical Institute investigator, and Margarita ... in the 2014 round of grants from the ... (Brain Research through Advancing Innovative Neurotechnologies) Initiative for ... 30, provides more than $3 million in funding ... The BRAIN Initiative, launched last year, is a ...
(Date:9/30/2014)... exposure to tetrachloroethylene (PCE) in drinking water may ... according to a new study led by a ... The study, published in the journal Environmental ... unexposed pregnancies among 1,766 women in Cape Cod, ... 1960s to the early 1980s by the installation ...
(Date:9/30/2014)... live in almost any aquatic environment on Earth, but ... species are pushed to the limit. The amount of ... critical for how different species cope in the future, ... of Gothenburg, published in the scientific journal Proceedings ... continues apace thanks to increasing levels of greenhouse gases ...
Breaking Biology News(10 mins):Salk scientists receive $3 million for BRAIN Initiative grant 2Contaminated water linked to pregnancy complications, BU study finds 2Shape up quickly -- applies to fish, too! 2
... treatment that spares disability from acute stroke may be ... ?a potential advance needed to benefit more stroke victims. ... that human umbilical cord blood cells administered to rats ... inflammatory response, reducing the size of the stroke and ...
... Universities of Heidelberg and Ulm and a unit of ... have discovered that a specific signal within brain cells ... stroke. Their study, published online (November 13) by Nature ... strokes could be developed by controlling a molecule involved ...
... EU-financed sleep research project is coordinated from FinlandIn ... network was establishedto investigate the causes and implications ... as from the social point of view. This ... effects of sleep restriction" will last for four ...
Cached Biology News:Cord blood cells may widen treatment window for stroke 2Limiting the damage in stroke 2Limiting the damage in stroke 3Do the Europeans turn ill sitting up so late? 2
CHIMAERIC HUMAN IgA2 ANTI NP...
ANTI NO-TRYPTOPHAN CONJUGATE...
... The Captivate magnetic separator ... be used in conjunction with ... C-21474, C-21476) or other magnetic ... most 96-well microplates. Cell Biology ...
Protein Phosphorylation...
Biology Products: